Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Envelope glycoprotein (Env) is a heavily glycosylated HIV-1 protein forming trimeric “spikes” on the virion surface, mediating receptor binding (via gp120) and fusion with host cells (via gp41).\nGroup-specific antigen (Gag) is a polyprotein cleaved into matrix (p17), capsid (p24), and nucleocapsid (p7) proteins, essential for virion assembly, RNA packaging, and particle release.\nPolymerase (Pol) is translated as part of Gag-Pol polyprotein; it encodes protease, reverse transcriptase, and integrase enzymes for proteolytic processing, genome replication, and integration.\nNegative regulatory factor (Nef) is an accessory protein involved in immune evasion, modulation of cell surface proteins, enhancement of viral infectivity, and downregulation of CD4 and MHC I on host cells.\nAll four are major antigens and targets in vaccine studies, with Env showing the greatest variability across viral strains and Gag/Pol more conserved. They are associated with disease progression and serve as primary molecular targets for antiretroviral drugs (primarily Pol) and experimental immunotherapies (Gag, Env, Nef).\nNote: For structured annotation, each protein (Env, Gag, Pol, Nef) should be treated as a separate target for precision. This bundled name is sometimes used in vaccine/antigen research but is not itself a canonical target name in pharmacology or molecular biology.
Reverse transcriptase inhibitors block DNA synthesis by Pol (reverse transcriptase)\nIntegrase inhibitors prevent viral DNA integration into host genome by Pol (integrase)\nProtease inhibitors block proteolytic maturation of viral polyproteins by Pol (protease)\nFusion inhibitors block Env-mediated membrane fusion\nMonoclonal antibodies neutralize Env\nVaccine approaches elicit immune responses targeting Gag, Pol, Env, and Nef antigens
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Envelope glycoprotein (Env), Group-specific antigen (Gag), Polymerase (Pol), Negative regulatory factor (Nef) of human immunodeficiency virus type 1 (HIV-1 Env, Gag, Pol, and Nef).